16 September 2026 editorial review · Item
Indigo HALO continuous multi-metabolite monitor: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Indigo HALO continuous multi-metabolite monitor
Scope and findings:
- ManufacturerexplicitnotFDAcleared/notCEmarked/notforsale;PLOSprimary7personfeasibility(glucoseMARD7.4%,4T1D)andnew12personHALOBRIGHTnotyetrecruitingJune2027completionverified. NotyearlongT1Defficacy.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.